CLOs on the Move

Novasyte

www.novasyte.com

 
Novasyte partners with med-tech companies, offering outsourced commercial service teams for clinical, sales, field technical and recall support. Our flexible model enables us to build, deploy and manage teams that expand and contract to meet our clients` customer-facing needs. Program success is tracked and measured with our real-time business intelligence analytics that provide our clients with critical insights into their most important resources - their people and their customers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.novasyte.com
  • 5999 Avenida Encinas Suite 100
    Carlsbad, CA USA 92008
  • Phone: 888.899.6682

Executives

Name Title Contact Details

Similar Companies

MCS-Medical Consulting and Solutions

MCS-Medical Consulting & Solutions is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orthopaedic Solutions

Orthopaedic Solutions is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MD Buyline

MD Buyline is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Volu-Sol

Volu-Sol is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSig

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.